1 January 2011 Two-dimensional singlet oxygen imaging with its near-infrared luminescence during photosensitization
Author Affiliations +
Photodynamic therapy is a promising cancer treatment that involves activation of photosensitizer by visible light to create singlet oxygen. This highly reactive oxygen species is believed to induce cell death and tissue destruction in PDT. Our approach used a near-infrared area CCD with high quantum efficiency to detect singlet oxygen by its 1270-nm luminescence. Two-dimensional singlet oxygen images with its near-infrared luminescence during photosensitization could be obtained with a CCD integration time of 1 s, without scanning. Thus this system can produce singlet oxygen luminescence images faster and achieve more accurate measurements in comparison to raster-scanning methods. The experimental data show a linear relationship between the singlet oxygen luminescence intensity and sample concentration. This method provides a detection sensitivity of 0.0181 μg/ml (benzoporphyrin derivative monoacid ring A dissolved in ethanol) and a spatial resolution better than 50 μm. A pilot study was conducted on a total of six female Kunming mice. The results from this study demonstrate the system's potential for in vivo measurements. Further experiments were carried out on two tumor-bearing nude mice. Singlet oxygen luminescence images were acquired from the tumor-bearing nude mouse with intravenous injection of BPD-MA, and the experimental results showed real-time singlet oxygen signal depletion as a function of the light exposure.
© (2011) Society of Photo-Optical Instrumentation Engineers (SPIE)
Bolin Hu, Bolin Hu, Nan Zeng, Nan Zeng, Zhiyi Liu, Zhiyi Liu, Yanhong Ji, Yanhong Ji, Weidong Xie, Weidong Xie, Qing Peng, Qing Peng, Yong Zhou, Yong Zhou, Yonghong He, Yonghong He, Hui Ma, Hui Ma, } "Two-dimensional singlet oxygen imaging with its near-infrared luminescence during photosensitization," Journal of Biomedical Optics 16(1), 016003 (1 January 2011). https://doi.org/10.1117/1.3528593 . Submission:

Back to Top